Cogeco has fallen to around C$53, near its 52-week low of C$53.50 and far below the C$77 level reached during the past year. The valuation looks increasingly interesting, but there is a major reason the market has become cautious. Third-quarter fiscal 2026 revenue declined 4.5% to C$724.2 million. Adjusted EBITDA remained strong at C$357.0 million, but the company reported a massive C$1.8 billion net loss after recognizing C$2.2 billion of non-cash impairment charges related mainly to its American telecommunications operations. Excluding these charges, adjusted profit attributable to shareholders increased to C$29.9 million from C$23.1 million. The American business remains the main problem. Revenue there fell 10.1%, reflecting subscriber losses and intense pricing competition. Canada performed better, while wireless growth and improving customer trends provide potential recovery drivers. The dividend is attractive and growing. The latest quarterly payment was C$0.987, 7% higher than a year earlier. From a value perspective, the stock combines depressed valuation, strong adjusted cash generation and a growing dividend with significant execution risk. Recovery could depend on stabilizing the United States business and restoring subscriber growth. The next results will be important. This review is for informational and educational purposes only, not financial advice.

Constellation Brands has fallen dramatically, with shares recently trading around $118, close to a multi year low. The selloff looks puzzling because the company is still generating strong cash flow and its beer business continues gaining market share. But the growth story has clearly slowed. In the first quarter of fiscal 2027, sales declined 3% to $2.43 billion, although comparable operating income increased 6% and comparable earnings per share rose 7%. Beer sales increased 2%, while beer operating margin remained an impressive 39%. Free cash flow reached $485 million. The bigger problem is future growth. Management expects fiscal 2027 organic sales to range from a 1% decline to 1% growth, while beer sales are expected to be similarly flat. Economic pressure, cautious consumers, weaker volumes and tariffs are weighing on expectations. There is still a shareholder return story. The quarterly Class A dividend increased from $1.01 in 2024 to $1.02 in 2025 and $1.03 in 2026. A recovery could come from renewed beer volume growth, stronger consumer spending and continued cash generation. Risks include weak demand, tariffs, leverage and stagnant growth. The next major catalyst is the October 6 earnings report. This review is for informational and educational purposes only, not financial advice.

Equasens has slipped to around €30.10, close to its 52 week low of €30.00 and roughly 35% below the recent high of €46.70. The timing is particularly interesting because the company still reports solid underlying growth. In 2025, revenue increased 9.1% to €236.5 million, while net profit rose 8.8% to €41.1 million. The operating margin remained above 20%, and net cash reached €83.6 million. Recurring revenue also grew 8.8%, providing an important source of visibility. The first quarter of 2026 brought another 7.7% increase in reported revenue to €61.4 million, although organic growth was more modest at 2.9%. The company has continued investing in acquisitions and technology, including its Erevo acquisition. The dividend is another attraction: €1.40 was approved for 2025, up from €1.25 for 2024. At €30.10, that represents a yield of about 4.7%. The immediate concern is a September fire that destroyed an ASCA facility and inventory. Equasens expects disruption to last about four weeks, although backup stock and its continuity plan should limit the impact. Recovery could depend on continued growth and successful integration. Risks include slower organic expansion, acquisition execution and temporary disruption. This review is for informational and educational purposes only, not financial advice.

Fidelity National Information Services has just hit a new 52 week low. Shares closed at $34.96 on September 22, down more than 49% from the $69.14 high. Yet the latest numbers tell a surprisingly different story. Second quarter revenue jumped 29% to $3.38 billion, while adjusted earnings per share increased 8.8% to $1.48. Adjusted earnings before interest, taxes, depreciation and amortization reached $1.41 billion, with the margin expanding to 41.7%. Free cash flow surged 220% to $525 million. The problem is not collapsing operations. Investors are worried about slower underlying growth, substantial debt following the Total Issuing Solutions acquisition, and a weaker outlook for organic expansion. Management reduced its 2026 pro forma revenue growth forecast to 4.5% to 5.0%. Debt stood at $21.2 billion at the end of June, making deleveraging an important priority. There is also a dividend story. The quarterly dividend increased 10% in 2026 to $0.44, compared with $0.40 in 2025 and $0.36 in 2024. At the current price, that represents a yield of roughly 5%. The potential recovery case rests on stronger cash generation, debt reduction, margin expansion and renewed investor confidence. The risks are leverage, slower growth, competition, cybersecurity and acquisition integration. This review is for informational and educational purposes only, not financial advice.

Manhattan Bridge Capital is trading near a fresh 52 week low, with shares closing at $3.89 on September 22, down sharply from the $5.79 52 week high. At first glance, the decline looks alarming. But underneath the falling share price sits a business still generating substantial cash and maintaining a double digit dividend yield. The problem is earnings momentum. Second quarter 2026 revenue fell 13.2% to $2.05 million, while net income declined 18.4% to $1.15 million. For the first six months, revenue decreased 11.1% and net income fell 12.9%. Management attributed much of the pressure to lower interest rates and origination fees caused by stronger competition. Still, loan originations and capital deployment increased, while shareholders’ equity stood at almost $43 million. The company also repurchased shares and continues targeting selective portfolio growth. The quarterly dividend is now $0.11, versus $0.115 during much of 2025. At the current price, that represents an annualized yield above 11%. The opportunity depends on stabilizing earnings and stronger lending activity. The risks are declining profitability, credit losses, competition and a potentially unsustainable payout. This review is for informational and educational purposes only, not financial advice.

Silvercrest Asset Management Group looks interesting after a sharp retreat. The latest Nasdaq close was $9.18 on September 22, down from $10.17 at the start of September and far below the levels above $10. The question is whether the market is pricing temporary pressure or a deeper earnings problem. The second quarter delivered mixed signals. Revenue was $30.8 million, essentially flat year over year, while total assets under management reached $37.0 billion. Discretionary assets under management rose 6.9% during the quarter, but net client outflows partly offset market gains. Expenses increased 12%, with compensation and administrative costs rising as management invests in future growth. Adjusted earnings before interest, taxes, depreciation and amortization fell to $3.4 million. The dividend is an attraction for value investors. The quarterly payout is now $0.21, compared with $0.20 in 2025, $0.19 in 2024 and $0.18 in 2023. At recent prices, the annualized yield is high. The key risk is that elevated costs and client outflows persist. A recovery could become more plausible if assets grow, expenses normalize, and international expansion improves organic inflows. This review is for informational and educational purposes only, not financial advice.

Tsingtao Brewery has fallen into a valuation zone that deserves a closer look. On September 23, the Shanghai listed shares traded around RMB 50.59, roughly 26% below the 52 week high. The decline looks striking because the business has not suffered a collapse in profitability. For the first half of 2026, revenue fell 4.1% to RMB 19.65 billion, yet net profit attributable to shareholders edged up 0.4% to RMB 3.92 billion. Gross margin improved to about 38%, while operating cash flow jumped 14.7%. Premium products continued gaining share, helping offset weaker demand. The valuation is now around 15 times earnings, with a dividend yield near 4.6%. The annual dividend increased from RMB 2.20 for 2024 to RMB 2.35 for 2025, although no interim dividend was declared for 2026. Why is the stock down? Weak Chinese consumer demand, lower sales volumes, and concerns about growth have pressured sentiment. The key recovery trigger would be renewed volume growth combined with continued margin expansion. The attraction: solid profitability, improving cash generation, rising dividends, and a depressed share price. The risks are clear: prolonged weak consumption, competitive pressure, and further earnings stagnation. This review is for informational and educational purposes only, not financial advice.

Olin has become a striking value-investing case. Shares recently traded around $16.50, close to their 52-week low of $16.35 and down roughly 46% from the 52-week high of $30.46. The decline reflects a serious earnings downturn, but the valuation is becoming increasingly difficult to ignore. Second-quarter 2026 revenue was $1.74 billion, down slightly year over year and below expectations. The company reported a $13.3 million net loss, or $0.12 per share, although adjusted EBITDA improved to $191.3 million from $176.1 million. The problem is that profitability remains weak. Olin has reported losses in recent quarters, while the chemical business faces difficult market conditions and cyclical pricing pressure. Trailing net income remains negative. There is nevertheless a potential recovery story. Adjusted EBITDA is improving sequentially, while management continues focusing on cost control and cash generation. The dividend remains $0.20 per quarter, or $0.80 annually, giving the shares a yield of almost 5% at the current price. The value case depends on chemical margins recovering and earnings returning to profitability. The risks are prolonged industry weakness, debt, volatile raw-material costs and continued losses. The next major catalyst is the third-quarter report, expected in late October. This review is for informational and educational purposes only, not financial advice.

Oxford Industries has suffered a brutal reset. Shares closed around $28.05, down more than 34% over the past year and nearly 27% since the end of August. The collapse accelerated after management sharply reduced its fiscal 2026 outlook. Is the market now pricing in too much bad news? Second-quarter revenue fell 2.2% to $394 million, although adjusted earnings per share increased to $1.34 from $1.26. The bigger problem is the outlook: management now expects fiscal 2026 revenue of $1.43–$1.47 billion and adjusted earnings per share of only $1.60–$2.00, versus $2.11 previously. Lilly Pulitzer remains under pressure, while tariffs and weaker consumer demand are weighing on profitability. There are positives. Gross margins have been improving, cash flow has helped reduce debt, and Tommy Bahama continues to perform relatively well. The company also pays a $0.70 quarterly dividend, recently increased from $0.69. The value case is straightforward: a depressed share price, recognizable brands, improving margins and potential earnings recovery. The risks are weak sales, continued pressure at Lilly Pulitzer, tariffs and a dividend that could become less comfortable if earnings remain depressed. A recovery depends on stronger consumer demand, successful brand improvements and restored profitability. At this valuation, the opportunity is significant, but so is the uncertainty. This review is for informational and educational purposes only, not financial advice.